Oligomeric compound for inhibiting expression of factor XI
US12378552B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 13, 2022 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | May 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Products, compositions, and their uses are provided. In particular, nucleic acid products that modulate, in particular interfere with or inhibit, Factor XI (FXI) gene expression are provided. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein said first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 1 to 250.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.